BACKGROUND AIMS: Bone marrow (BM)-derived cells may repair cardiovascular injury but populations of interest circulate in small numbers. Cytokines such as granulocyte-colony-stimulating factor mobilize cells under investigation for this purpose, including CD133+ but require injections over multiple days and may promote inflammation. The purpose of this study was to evaluate the effects of a novel CXCR4 inhibitor (plerixafor), previously shown to mobilize CD34+ stem cells, on CD133+ mobilization and markers of inflammation. METHODS: Healthy subjects received a single subcutaneous injection of plerixafor in escalating doses: 240 mcg/kg (n = 3), 320 mcg/kg (n = 5) and 400 mcg/kg (n = 7). CD133+ and CD133+/VEGFR-2+ cells were measured by flow cytometry at baseline, then 4-6 h following plerixafor injection. Markers of inflammation in serum were measured at baseline, then again 10 h following injection of the 400 mcg/kg dose. RESULTS: Across all doses, white blood cells increased on average three-fold from baseline values. CD133+ cells increased on average 24-fold (from 616 +/- 141 cells/mL to 14 713 +/- 4423 cells/mL, P = 0.0064) without clear evidence of a dose effect. CD133+/VEGFR-2+ cells ranged from 0 to 20 cells/mL at baseline and from 0 to 124 cells/mL following plerixafor administration, although the rarity of these cells precluded a statistical analysis of this population. C-reactive protein and serum amyloid type A were not increased after the 400 mcg/kg dose. Pro-inflammatory cytokine levels were undetectable before and after plerixafor, except for macrophage inflammatory protein-1 beta, which increased slightly but significantly after the 400 mcg/kg dose of plerixafor (P = 0.0156). CONCLUSIONS: CD133+ cells are mobilized into the circulation following a single injection of the CXCR4 antagonist plerixafor, without clear evidence for systemic activation of inflammation. This effect may be of importance in cell-based approaches for treating cardiovascular diseases.
BACKGROUND AIMS: Bone marrow (BM)-derived cells may repair cardiovascular injury but populations of interest circulate in small numbers. Cytokines such as granulocyte-colony-stimulating factor mobilize cells under investigation for this purpose, including CD133+ but require injections over multiple days and may promote inflammation. The purpose of this study was to evaluate the effects of a novel CXCR4 inhibitor (plerixafor), previously shown to mobilize CD34+ stem cells, on CD133+ mobilization and markers of inflammation. METHODS: Healthy subjects received a single subcutaneous injection of plerixafor in escalating doses: 240 mcg/kg (n = 3), 320 mcg/kg (n = 5) and 400 mcg/kg (n = 7). CD133+ and CD133+/VEGFR-2+ cells were measured by flow cytometry at baseline, then 4-6 h following plerixafor injection. Markers of inflammation in serum were measured at baseline, then again 10 h following injection of the 400 mcg/kg dose. RESULTS: Across all doses, white blood cells increased on average three-fold from baseline values. CD133+ cells increased on average 24-fold (from 616 +/- 141 cells/mL to 14 713 +/- 4423 cells/mL, P = 0.0064) without clear evidence of a dose effect. CD133+/VEGFR-2+ cells ranged from 0 to 20 cells/mL at baseline and from 0 to 124 cells/mL following plerixafor administration, although the rarity of these cells precluded a statistical analysis of this population. C-reactive protein and serum amyloid type A were not increased after the 400 mcg/kg dose. Pro-inflammatory cytokine levels were undetectable before and after plerixafor, except for macrophage inflammatory protein-1 beta, which increased slightly but significantly after the 400 mcg/kg dose of plerixafor (P = 0.0156). CONCLUSIONS:CD133+ cells are mobilized into the circulation following a single injection of the CXCR4 antagonist plerixafor, without clear evidence for systemic activation of inflammation. This effect may be of importance in cell-based approaches for treating cardiovascular diseases.
Authors: Y Fukumoto; T Miyamoto; T Okamura; H Gondo; H Iwasaki; T Horiuchi; S Yoshizawa; S Inaba; M Harada; Y Niho Journal: Br J Haematol Date: 1997-06 Impact factor: 6.998
Authors: Jonathan M Hill; Mushabbar A Syed; Andrew E Arai; Tiffany M Powell; Jonathan D Paul; Gloria Zalos; Elizabeth J Read; Hanh M Khuu; Susan F Leitman; McDonald Horne; Gyorgy Csako; Cynthia E Dunbar; Myron A Waclawiw; Richard O Cannon Journal: J Am Coll Cardiol Date: 2005-11-01 Impact factor: 24.094
Authors: David Stroncek; Stefanie Slezak; Hanh Khuu; Christopher Basil; John Tisdale; Susan F Leitman; Francesco M Marincola; Monica C Panelli Journal: Exp Hematol Date: 2005-10 Impact factor: 3.084
Authors: Jennifer K Pai; Tobias Pischon; Jing Ma; JoAnn E Manson; Susan E Hankinson; Kaumudi Joshipura; Gary C Curhan; Nader Rifai; Carolyn C Cannuscio; Meir J Stampfer; Eric B Rimm Journal: N Engl J Med Date: 2004-12-16 Impact factor: 91.245
Authors: Tiffany M Powell; Jonathan D Paul; Jonathan M Hill; Michael Thompson; Moshe Benjamin; Maria Rodrigo; J Philip McCoy; Elizabeth J Read; Hanh M Khuu; Susan F Leitman; Toren Finkel; Richard O Cannon Journal: Arterioscler Thromb Vasc Biol Date: 2004-11-29 Impact factor: 8.311
Authors: Q Shi; S Rafii; M H Wu; E S Wijelath; C Yu; A Ishida; Y Fujita; S Kothari; R Mohle; L R Sauvage; M A Moore; R F Storb; W P Hammond Journal: Blood Date: 1998-07-15 Impact factor: 22.113
Authors: P Anderlini; M Körbling; D Dale; A Gratwohl; N Schmitz; D Stroncek; C Howe; S Leitman; M Horowitz; E Gluckman; S Rowley; D Przepiorka; R Champlin Journal: Blood Date: 1997-08-01 Impact factor: 22.113
Authors: Steven M Devine; Neal Flomenberg; David H Vesole; Jane Liesveld; Daniel Weisdorf; Karin Badel; Gary Calandra; John F DiPersio Journal: J Clin Oncol Date: 2004-03-15 Impact factor: 44.544